Takamitsu Hattori
Overview
Explore the profile of Takamitsu Hattori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirose T, Nakazawa H, Hattori T, Ishigaki Y, Umetsu M
Langmuir
. 2025 Mar;
PMID: 40064552
Inorganic material-binding proteins are valuable tools for conjugating different inorganic materials. The development of efficient methods for obtaining high-affinity inorganic material-binding proteins is desirable. In this study, focusing on ZrO,...
2.
Riso M, Shah R, Koide A, Ruthenburg A, Koide S, Hattori T
Proc Natl Acad Sci U S A
. 2025 Jan;
122(1):e2411720121.
PMID: 39793060
Posttranslational modifications (PTMs) of proteins play critical roles in regulating many cellular events. Antibodies targeting site-specific PTMs are essential tools for detecting and enriching PTMs at sites of interest. However,...
3.
Bang I, Hattori T, Leloup N, Corrado A, Nyamaa A, Koide A, et al.
Nat Chem Biol
. 2024 Oct;
PMID: 39438724
Oncogenic mutations in the extracellular domain (ECD) of cell-surface receptors could serve as tumor-specific antigens that are accessible to antibody therapeutics. Such mutations have been identified in receptor tyrosine kinases...
4.
Maso L, Rajak E, Bang I, Koide A, Hattori T, Neel B, et al.
Proc Natl Acad Sci U S A
. 2024 May;
121(22):e2319029121.
PMID: 38781214
The HapImmune platform exploits covalent inhibitors as haptens for creating major histocompatibility complex (MHC)-presented tumor-specific neoantigens by design, combining targeted therapies with immunotherapy for the treatment of drug-resistant cancers. A...
5.
Ravn-Boess N, Roy N, Hattori T, Bready D, Donaldson H, Lawson C, et al.
Cell Rep
. 2023 Nov;
42(11):113374.
PMID: 37938973
Glioblastoma (GBM) is the most common and aggressive primary brain malignancy. Adhesion G protein-coupled receptors (aGPCRs) have attracted interest for their potential as treatment targets. Here, we show that CD97...
6.
Akkapeddi P, Hattori T, Khan I, Glasser E, Koide A, Ketavarapu G, et al.
Proc Natl Acad Sci U S A
. 2023 Jul;
120(28):e2302485120.
PMID: 37399416
The G12D mutation is among the most common KRAS mutations associated with cancer, in particular, pancreatic cancer. Here, we have developed monobodies, small synthetic binding proteins, that are selective to...
7.
Deng J, Peng D, Fenyo D, Yuan H, Lopez A, Levin D, et al.
bioRxiv
. 2023 May;
PMID: 37131623
Significance: Loss-of-function mutations in the tumor suppressor of lung adenocarcinoma patients and are associated with resistance to current treatments. Our study identified CD38 as a potential therapeutic target that is...
8.
Hattori T, Maso L, Araki K, Koide A, Hayman J, Akkapeddi P, et al.
Cancer Discov
. 2022 Oct;
13(1):132-145.
PMID: 36250888
Significance: Targeted therapies against oncoproteins often have dramatic initial efficacy but lack durability. Immunotherapies can be curative, yet most tumors fail to respond. We developed a generalizable technology platform that...
9.
Romero L, Hattori T, Ali M, Ketavarapu G, Koide A, Park C, et al.
J Mol Biol
. 2021 Dec;
434(5):167402.
PMID: 34958778
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that currently requires intensive chemotherapy. While childhood T-ALL is associated with high cure rates, adult T-ALL is not, and...
10.
Koide A, Panchenko T, Wang C, Thannickal S, Romero L, Teng K, et al.
bioRxiv
. 2021 Aug;
PMID: 34373852
Antibody responses serve as the primary protection against SARS-CoV-2 infection through neutralization of viral entry into cells. We have developed a two-dimensional multiplex bead binding assay (2D-MBBA) that quantifies multiple...